DRUG SUPPLIED DOSE COMMENTS
ADALIMUMAB (Paeds)
(Humira)

Mechanism of action:

Anti TNFalpha antibody



Ref:
321, 322, 323, 324, 505

Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433-1441.

Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257-291.




Last update: 2021-06-23		 Injection:
40 mg in 0.8 mL pre-filled syringe

40 mg / 0.8 mL vials		 Refractory Juvenile Idiopathic Arthritis (JIA) and uveitis:
24 mg/ m2 /dose SC Q2wks
2 to 4 yrs: Max 20 mg/dose
>4 yrs: Max 40 mg/dose
Alternate dosing:
< 30 kg: 20 mg/dose SC Q2wks
>= 30 kg: 40 mg/dose SC Q2wks

Adolescent Hidradenitis Suppurativa:
30 to <60 kg: 80 mg SC day 1, 40 mg SC day 8, then 40 mg SC Q2wks
>= kg: 160 mg SC day 1, 80 mg SC day 15, then 40 mg SC Qweekly

Crohn's Disease (moderate-severe, refractory):
Initial: 2.4 mg/kg/dose (Max 160 mg/dose) SC at week 0, followed by 1.2 mg/kg/dose (Max 80 mg/dose) at week 2
Maintenance: 0.6 mg/kg (Max 40 mg/dose) Q2wks beginning at week 4

Ulcerative Colitis:
Initial: 100 mg/m2/dose (Max 160 mg/dose) at week 0, then 50 mg/m2/dose (Max 80 mg/dose) at week 2
Maintenance: 25 mg/m2/dose Q2wks (Max 40 mg/dose) beginning at week 4

 For subcutaneous administration only.

Adverse effects include injection site irritation, headache, dizziness, cough, diarrhea, nausea, vomiting, rash, fever and infection.

Risk of infection: do not use in patients with active infection. All patients should be evaluated for both active and latent tuberculosis before starting treatment.

Administration of live vaccinations to patients on adalimumab not recommended.



Standard Prescription:

Adalimumab __ mg SC